Merger Agreement with
Deciphera Pharmaceuticals

April 30, 2024

Cautionary Note Regarding Forward-Looking Statements
This communication relates to ONO Pharmaceutical co., ltd. (“ONO”), Deciphera Pharmaceuticals, Inc (“Deciphera”) and the proposed acquisition of Deciphera by ONO (the “Proposed Transaction”) andincludes express or implied forward-looking statements about the Proposed Transaction, the operations of the combined company and the anticipated benefits of the Proposed Transaction that involve risks
and uncertainties relating to future events and the future performance of ONO and Deciphera. Actual events or results may differ materially from these forward-looking statements. Words such as “will,”“could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” variations of such words, and similar expressions are intended to
identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or
implied: statements regarding the Proposed Transaction and related matters, closing conditions, prospective performance and opportunities, post-closing operations and the outlook for the companies’
businesses; statements of targets, plans, objectives or goals for future operations, including those related to ONO’s and Deciphera’s products, product research, product development, product introductions
and product approvals as well as cooperation in relation thereto; statements containing projections of or targets for financial performance or other financial measures; statements regarding outcome ofcontingencies such as legal proceedings; and statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By
their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause
actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include,
without limitation: uncertainties as to the timing of the Proposed Transaction (including the tender offer and merger); uncertainties as to how many of Deciphera’s stockholders will tender their stock in theoffer; the possibility that competing offers will be made; the possibility that various closing conditions for the Proposed Transaction may not be satisfied or waived, including that a governmental entity may
prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of
regulatory approvals or actions, if any; the possibility that the Proposed Transaction may not be completed in the time frame expected by ONO and Deciphera, or at all; failure to realize the anticipated benefitsof the Proposed Transaction in the time frame expected, or at all; the effects of the Proposed Transaction on relationships with employees, other business partners or governmental entities; potential adverse
reactions or changes to business relationships resulting from the announcement or completion of the Proposed Transaction; significant or unexpected costs, charges or expenses resulting from the Proposed
Transaction; negative effects of this announcement or the consummation of the Proposed Transaction on the market price of Deciphera’s common stock and/or ONO’s or Deciphera’s operating results;
unknown liabilities; the risk of litigation and/or regulatory actions related to the Proposed Transaction; global as well as local political and economic conditions, including interest rate and currency exchange
rate fluctuations; delay or failure of projects related to research and/or development; unplanned loss of patents; interruptions of supplies and production, product recalls, unexpected contract breaches or
terminations; government-mandated or market-driven price decreases for ONO’s or Deciphera’s products; introduction of competing products; reliance on information technology; ONO’s or Deciphera’s ability
to successfully demonstrate the efficacy and safety of their drug or drug candidates; the preclinical or clinical results for ONO’s or Deciphera’s product candidates, which may not support further developmentof such product candidates; Deciphera’s ability to commercialize QINLOCK ® and execute on its marketing plans for any drugs or indications that may be approved in the future; ONO’s, Deciphera’s, and theircollaborators’ ability to continue to conduct research and clinical programs; exposure to product liability and legal proceedings and investigations; changes in governmental laws and related interpretation
thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing; perceived or actual failure to adhere to ethical marketing
practices; investments in and divestitures of domestic and foreign companies; unexpected growth in costs and expenses; failure to recruit and retain the right employees; failure to maintain a culture ofcompliance; and epidemics, pandemics or other public health crises and their impact on ONO’s and Deciphera’s respective businesses, operations, supply chain, patient enrollment and retention, clinical trials,
strategy, goals and anticipated milestones. A more complete description of these and other material risks can be found in Deciphera’s filings with the SEC, including its annual report on Form 10-K for the year
ended December 31, 2023 and other documents that may be filed from time to time with the U.S. Securities and Exchange Commission (the “SEC”), as well as the Schedule TO and related tender offer
documents to be filed by ONO and its wholly owned subsidiary (special purpose company) (“Purchaser”), and the Schedule 14D-9 to be filed by Deciphera.
Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs and judgments of ONO’s and Deciphera’s management, and the reader iscautioned not to rely on any forward-looking statements made by ONO or Deciphera. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Unlessrequired by law, neither ONO nor Deciphera is under any duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new
information, future events or otherwise.

1 / 25

Additional Information and Where to Find It
The tender offer referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell
securities of Deciphera, nor is it a substitute for the tender offer materials that Deciphera, ONO or Purchaser will file with the SEC. The solicitation and offer to buy Deciphera stock will only be made pursuant
to an Offer to Purchase and related tender offer materials that ONO intends to file with the SEC. At the time the tender offer is commenced, ONO will file a Tender Offer Statement on Schedule TO andthereafter Deciphera will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. DECIPHERA’S STOCKHOLDERS AND OTHER INVESTORS ARE
URGED TO READ CAREFULLY THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER
DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY WILL EACH CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF
DECIPHERA SECURITIES AND OTHER INVESTORS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, therelated Letter of Transmittal, certain other tender offer documents, as well as the Solicitation/Recommendation Statement will be made available to all stockholders of Deciphera at no expense to them and will
also be made available for free at the SEC’s website at www.sec.gov. Copies of the documents filed with the SEC by Deciphera will be available free of charge on Deciphera’s website athttps://investors.deciphera.com/sec-filings.
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Deciphera files annual, quarterly andcurrent reports and other information with the SEC. You may read and copy any reports or other information filed by Deciphera at the SEC public reference room at 100 F Street, N.E., Washington, D.C.
20549. Deciphera’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.

2 / 25

Agenda01

Transaction Summary

02

Ono’s Growth Strategy

03

Overview of Deciphera Pharmaceuticals, Inc.

04

Strategic Rationale of Acquisition

3 / 25

01
Transaction Summary

Transaction Summary
Party

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)

PurchasePrice

US $25.60 per share in cash; Total equity value of acquisition is approximately US $2.4 billion(Premium of 74.7% to Deciphera’s closing share price of US $14.65 on April 26, 2024, and premium of 68.8%
to Deciphera’s 30 trading day volume weighted average price of as of April 26, 2024)

Acquisition
Method／Financing

Cash tender offer, followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with
Deciphera surviving as a wholly owned subsidiary of ONO／Financed through cash on hand and bank loans; no financing contingency

ClosureTransaction is conditional upon the tender of a majority of Deciphera's outstanding shares of common stock,
antitrust authorities, and the satisfaction of other closing conditions

Schedule

Acquisition is expected to close during 2Q of ONO’ FY2024 (third calendar quarter of 2024)

Pro-forma
Structure

Upon completion of the Acquisition, Deciphera will operate as a standalone business of ONO Group, from its
headquarters in Waltham, Massachusetts

Financial
ImpactImpact of this acquisition on our financial performance is currently under review
The consolidated earnings forecast for the FY2025 scheduled to be announced on May 9 will be released without incorporating the effects of thisacquisition, as it is still being reviewed. Should there be any matters that require reporting in the future, we will promptly make an announcement.

5 / 25

02
Ono’s Growth Strategy

Growth Strategy to Become Global Specialty Pharma
Aiming to be a ‘Global Specialty Pharma’ that consistently delivers innovative drugs worldwide,
we strategically focus on enhancing our global pipeline and realizing direct sales in the U.S. and Europe
Reinforcement of pipelines and acceleration of global development

Realization of direct sales in the US and Europe⚫ Expanding the pipeline in 4 key areas through collaboration
between Research, Clinical Development, and BD / License⚫ Building a global development organization to handle
operation from clinical trials to regulatory approval in-house⚫ Office relocated to Cambridge, Massachusetts on DATE
⚫ We are building our organization for the launch of Velexbru®
by hiring in Commercial, PV, Medical and other functions(currently, 120 staff in the U.S. and 50 in Europe)

Oncology

Immunology

Step
4 Priority
Areas

Neurology

Specialty

1

Step

2

U.S. & Europe

KR & TW, Asia

ExpandingGlobalizing
own marketing
operations

own marketing
operations into
U.S. and Europe

Launched own marketing
South Korea(2015)
Taiwan(2016)

Launching development
and marketing operations
in U.S. and Europe

Step

3

GlobalBecominga true global
company

Expanding global
development activities andmarketing operations

7 / 25

Growth Strategy to Become Global Specialty Pharma
Acquiring promising global pipelines and strengthening the overseas capability by M&A is means toaccelerate our activity for growing towards a Global Specialty Pharma by realizing direct sales1’) Development or acquisition of ANOTHER promising global pipelines

3) Building a strong global presence and reinvesting profits for further growth2) Maximizing product value by strengthen sales expertise in U.S. and Europe

1) Development or acquisition of promising global pipelines

8 / 25

03
Overview of Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Company focusing on discovering, developing and commercializing new medicines for cancer, with richpipeline of oral kinase inhibitors (founded 2003)【U.S.】 Waltham, Massachusetts (Headquarters), Lawrence, Kansas (Research)

Strong U.S.
and European
Footprint【Europe】 Zug (Switzerland), Munich (Germany), Paris (France), Milan (Italy), Barcelona (Spain),
Amsterdam (Netherlands)

Leadership⚫ Steven L. Hoerter（President, Chief Executive Officer）

Pipeline

Financial
Information(last 3-year)⚫ QINLOCK®

GIST1) 4th line ／approved in >40 countries, GIST 2nd line KIT Exon 11+17/18 ／Phase 3⚫ Vimseltinib

TGCT2)／Regulatory Submission, cGVHD3)／Preparing for Phase 2 POC in 2H 2024

⚫ DCC-3116

KRAS G12C mutated cancer and GIST／Phase 1b⚫ DCC-3084

Cancer／P1 preparation⚫ DCC-3009

GIST／IND in 2024
FY 2021

FY 2022

FY 2023

Revenue (in thousands USD)

96,148134,036

163,356

Total Equity (in thousands USD)

304,720

341,691

350,916

Equity per share (USD)

5.25

4.53

4.13

1) Gastrointestinal Stromal Tumor, 2) Tenosynovial Giant Cell Tumor, 3) chronic Graft-Versus-Host Disease

10 / 25

Deciphera’s Strong Oncology Portfolio and Compelling Pipeline
Proven track records in R&D and sales with 5 proprietary first in class or best in class products andpipelines in oncology therapeutic area
Product and late-stage pipelines

Sales expertise in the U.S. and Europe⚫ QINLOCK® : approved in >40 countries, with 2023 sales of$163M, and plan for additional indication⚫ Vimseltinib : planned for NDA / MAA filing in 2024

⚫ QINLOCK® : Direct sales in U.S. and 6 European countries⚫ Vimseltinib : Complementary commercial opportunity with
QINLOCK® , 70-80% overlap in U.S. prescribing physiciansfor GIST and TGCT

Early-stage pipeline

Propriety discovery platform⚫ Proprietary 3 assets in oncology therapeutic area,
including FIC mechanism of action⚫ Proprietary Switch Control Platform allows for design ofhighly selective drug candidates⚫ All compounds in clinical stage are discovered by
Deciphera

Experienced management team
⚫ Deep knowledge of market practice in U.S. and Europe with decades of expertise in biotechnology and pharmaceutical industry

11 / 25

Overview of QINLOCK®
Only approved drug for 4th line GIST1) in the U.S., Europe, and other countries around the globe

Characteristic

Mechanism of
ActionDevelopment

Sales

Collaboration

The most common sarcoma of the gastrointestinal tract andpresent in the stomach or small intestine
The total number of annual cases in U.S. and Europe is
4,000 ~ 5,000 patients for each2)

KIT Inhibitor／Small molecule (oral)

1. GIST 4th line : Approved (US 2020, EU 2021) *2. GIST 2nd line KIT exon 11+17/18 : Phase 3 *⃰ Both granted US FDA Breakthrough Therapy Designation

Product Positioning

1st Line

2nd Line

3rd Line

4th Line

Imatinib

Sunitinib

Regorafenib

QINLOCK®

Potential to Optimize
2L Therapy Based on
Mutations

Established 4L SOC
Across All Mutations

Approved in >40 Countries

Global revenue in 2023 : $163M

Zai Lab collaboration for Greater China from 20191) Gastrointestinal Stromal Tumor
2) ONO market survey in 2024

12 / 25

Summary of INVICTUS Study: 4th line GIST
INVICTUS results showed a statistically significant improvement in PFS; clinically meaningfulimprovement in OS (BTD1))
DesignA Phase 3, randomized, double-blind, placebo-controlled study (29 sites in 12 countries)

CohortQINLOCK® 150mg once daily (n=80), Placebo (n=40)

SafetyGrade 3/4 AE frequency similar in both cohorts (QINLOCK® 49.4%, Placebo 44.2%)

Primary Endpoint: PFS

Secondary Endpoint: OS

84% Risk Reduction

59% Risk Reduction

HR=0.16 (95% CI, 0.1-0.27)

HR=0.41 (95% CI, 0.26-0.65)
QINLOCK®

Placebo

QINLOCK®

Placebo1) US FDA Breakthrough therapy designation, figure is cited from Blay JY et al. Lancet Oncol. (2020),von Mehren M et al. ESMO Poster Presentation (2021)

13 / 25

Exploratory Analysis From INTRIGUE Study: 2nd line GIST
Although the primary endpoint was not achieved, the results of this exploratory analysis demonstrate theimpressive clinical efficacy for QINLOCK® in patients with KIT exon 11+17/18 mutations (BTD1) )DesignA phase 3, randomized, open-label, study versus Sunitinib (121 sites in 22 countries)

CohortQINLOCK® 150mg once daily (n=226), Sunitinib 50mg once daily2) (n=227)

PFS (KIT exon 11+17/18 patients)

OS (KIT exon 11+17/18 patients)

78% Risk Reduction
HR=0.22 (95% CI, 0.11-0.44)

QINLOCK®

QINLOCK®
Sunitinib
Sunitinib

QINLOCK

Numberat risk
QINLOCK
Sunitinib

27
25

27
20

25
18

23
16

23
16

23
15

21
10

18
8

16
8

12
6

8
5

5
2

1
0

1

0

A new Phase 3 (INSIGHT) study in 2nd line GIST patients with KIT exon 11+17/18 is ongoing
1) US FDA Breakthrough therapy designation, 2) 4weeks on, 2weeks off
Michael C. Heinrich et al, Nature Medicine (2024)

14 / 25

Market Potential of QINLOCK®
QINLOCK® business is in a growth phase with rising revenue; opportunity exists for significant upside
potential with new indications and continued geographic expansion
Revenue increase (quarterly)

Expanding distribution channel in Europe

Revenue has increased steadily quarter over quarter; further
growth potential with new indication in 2nd line GIST with KIT
exon 11+17/18 mutations

Direct sales in U.S. and 6 European countries1);
Building broader distribution channel by direct sales and/or
through partnering activities is continuously ongoing

1) France : Expanded Access Program / Switzerland : Named Patient Sales;
cited from Deciphera’s Corporate Presentation (February, 2024)

15 / 25

Overview of Vimseltinib
Potential best-in-class CSF1R inhibitor preparing for NDA / MAA filing for TGCT1) in U.S. and Europe⚫ Locally aggressive tumors in joints⚫ High disease burden withmultiple symptoms including
severe pain, limited function,
Characteristicswelling, and stiffness⚫ The total number of all cases in
U.S. and Europe is 15,000 patientsfor each2)
Mechanism of
ActionCSF1R Inhibitor／Small molecule (oral)

Development

1. TGCT：Phase 3 MOTION trial met primary andall key secondary endpoints; US NDA and EU MAA
filings planned Q2 and Q3 2024, respectively
2. cGVHD3)：Phase 2 POC study to be initiated in
2H 2024

Sales
Strategy

Product Positioning (U.S.)
surgery

Diagnosis
not amenable
surgery

recurrence

SystemicTreatment

Off-label use of Imatinib etc.
Turalio (CSF-1R inhibitor)
Succeeded from positive Phase 3
MOTION trial in this segment

Market Size in U.S. & EU

Complementary commercial opportunity with
QINLOCK® , 70-80% overlap in U.S. prescribing
physicians for GIST and TGCT
1) Tenosynovial Giant Cell Tumor2) Deciphera’s Corporate Presentation (February, 2024)
3) chronic Graft-Versus-Host Disease

16 / 25

Summary of MOTION Study: TGCT
Demonstrated statistically significant improvement in ORR and met all six key secondary endpoints,
including TVS1) and ROM2)
DesignA Phase 3, randomized, double-blind3), placebo-controlled study (35 sites in 13 countries)

CohortVimseltinib 30mg twice weekly (n=83), Placebo3) (n=40)

Primary Endpoint: ORR

Secondary Endpoint: TVS1)

Secondary Endpoint: ROM2)(at week 25)(at week 25)(at week 25)

50%

40%

p<0.0001
40%

80%

p<0.0001

67%30%

p=0.0077

18.4%

60%
20%

30%
40%
20%

10%
20%

10%
0%

0%

0%

3.8%
0%

0%

Placebo

Vimseltinib

Placebo

Vimseltinib

Placebo

Vimseltinib

n=40(95%CI: 0%,9%)n=83(95%CI: 29%,51%)

n=40(95%CI: 0%,9%)n=83(95%CI: 56%,77%)

n=38(Baseline 62.9%)

n=79(Baseline 63.0%)

Above figures are edited from Deciphera‘s Earnings Conference Call materials
1) Tumor Volume Score, 2) Active range of motion, 3) Part 1: Double-Blind for 24 weeks, Part2: Open-Label (Patients had the option to cross over to Vimseltinib 30mg twice weekly)

17 / 25

Deciphera’s Pipeline
Robust Pipeline from Deciphera’s Proprietary Switch Control Platform
Pipeline

Indication

Stage

GIST 4th line

Approved >40 countries(US 2020, EU 2021)

GIST 2nd line
KIT exon 11+17/18

P3

TGCT

Regulatory Submission

cGVHD

P2 (2H 2024)

ULK

KRAS G12C
mutated cancer and
GIST

P1b

DCC-3084

Pan-RAF

Solid Tumors andHematologic
Malignancies

P1 preparation

DCC-3009

Pan-KITGIST

IND in 2024

QINLOCK®

Vimseltinib

DCC-3116

TargetOriginator

Switch Control Kinase Inhibitor

KIT

CSF-1R

The concept is to bind both switch pocket
region and the activation loop to lock the
kinase in an inactive state

Deciphera’s website

18 / 25

Market Opportunity for Deciphera’s pipeline
QINLOCK® and Vimseltinib together are expected to represent a peak worldwide revenue opportunity of$1B; upside potential expected with label expansions and advancements of other early-stage assets​
DCC-3116
DCC-3084
DCC-3009

DCC-3116 : Target population ～10,000 patients4)
DCC-3084 : Target population ～15,000 patients4)
DCC-3009 : Target population ～ 1,600 patients4)
U.S. market for cGVHD is expected to grow to ～$1B3)+αVimseltinib
Total Addressable U.S. Market for TGCT is $700M2)+ ~$1B+ ~$700M

QINLOCK®

With expanding the indication in 2nd line GIST
patients with KIT exon 11+17/18 mutations,$350M ~ $400M is expected as U.S. peak revenue1)$350～400M

1), 2) Deciphera’s Corporate Presentation (February, 2024)
3) ONO market survey in 2024
4) U.S. target population estimated by ONO

19 / 25

Deciphera’s Strong U.S. and European Footprint
R&D and CMC functions are based in the U.S., and Commercial organization is Established in the U.S.
and 6 European countries (355 employees in total 1))
United States[Head Office (Development / Regulatory / Sales / BD / CMC)]
Location: Waltham, MA[Research]
Location: Lawrence, Kansas

Europe[European Commercial Headquarters]
Location: Zug (Switzerland)[European Marketing Branch]
Location: Munich (Germany) / Paris (France) /Milan (Italy) / Barcelona (Spain) / Amsterdam (Netherlands)

1) Deciphera’s Corporate Presentation (February, 2024)

20 / 25

04
Strategic Rationale of Acquisition

Strategic Rationale of Acquisition
The acquisition of Deciphera is a pivotal growth driver toward becoming a Global Specialty Pharma

Reinforcement ofpipeline inoncology
therapeutic area

Reinforcement ofsales anddevelopment teamin U.S. & EU

Reinforcement ofexpertise in kinasedrug discovery⚫ QINLOCK® ; launched product in U.S. and Europe⚫ Vimseltinib ; marketing applications in U.S. andEurope in Q2/Q3 2024
⚫ Multiple pipeline in clinical stage⚫ Secure short to mid-term revenue⚫ Addressing forthcoming LOE of diabetes
drugs and decrease in PD-1-related royalty
revenue⚫ Experienced development, regulatory affairs,
and sales / marketing teams in oncology andspecialty field⚫ Accelerating globalization in parallel with
U.S & EU, which potentially advantage
future collaboration activities⚫ Know-how and platform with track records ofcreating multiple pipelines by a researchorganization⚫ Contribution for mid to long-term growthby continuing creation of pipelines

22 / 25

Brings Together Complementary Strength of Ono and Deciphara
Accelerate growth towards Global Specialty Pharma by leveraging strength of each company
Accelerate growth towards
Global Specialty Pharma
Expertise of sales and developmentin the field of
IO and hematologic cancer

Expertise of sales and developmentin the field of solid tumor

Build a more robust presence
in oncology field

Sales Capability in Japan and Asia;
Development Capability in Japan,
Asia, UK and U.S.

Sales and development Capabilities
in U.S. and Europe

Reinforcement of global
development and sales capability

Substantial investment
in R&D Activities

Advanced expertisein drug discovery and development

Continuing creation ofnovel pipelines

Investment in various modalities;
Open innovation

Proprietary platformin the kinase field

Bring new innovation

23 / 25

Reinforcement of Global Pipeline through this transaction
Enrichment of global pipelines1), especially in oncology field, which encourage us to strengthen
franchises in the hematologic cancer and gastrointestinal areas
PoC

Regulatory・Approval

PivotalLeveraging QINLOCK®’s sales infrastructure to enhancecompetitive advantage in the gastrointestinal field

ONO-7475

ONO-4578

PDAC, EGFR mut NSCLC／P1

Gastric cancer／P2

ONO-8250

ONO-4578

QINLOCK®

HER2+ solid tumor／P1

CRC, PDAC, NSCLC, HER2neg BC／P1

GIST／Launched

Solid tumor

DCC-3084

ONO-7914

Vimseltinib

Solid tumor／P1

Solid tumor／P1

TGCT／Regulatory Submission

DCC-3009

DCC-3116

GIST／P1 preparation

Solid tumor／P1

80% Overlap of sales region, enabling toleverage QINLOCK®’s sales infrastructure

ONO-7018

Velexbru®／ONO-4059

NHL, CLL／P1

PCNSL／P2

Hematologic
cancer／other blood
diseaseONO-4685

Vimseltinib

Itolizumab2)

T-cell Lymphoma／P1

cGVHD／P2 preparation

aGVHD／P3

Immunology/
Specialty

ONO-4685

Velexbru®／ONO-4059

Autoimmune disease／P1

Pemphigus／P3

ONO-2020

ONO-2808

Neurodegenerative disease／P1

Multiple System Atrophy／P2

Neurology
ONO-1110
Pain／P1

Leveraging Velexbru®’s sales
infrastructure to enhancecompetitive advantage in the
Hematologic cancer and otherblood disease field

ONO-2910
Diabetic polyneuropathy, ChemotherapyInduced Peripheral Neuropathy／P2

1) Compounds currently developed or potentially developed in future in U.S. and EU
2) Equillium grants Ono an option to purchase right to Itolizumab in territories including U.S., Canada, Australia, and New Zealand in December 2022

24 / 25

Growth Strategy to Become Global Specialty PharmaCounteracting the patent cliff and reinforcing our business capability in U.S and Europe, we expect toimplement more global licensing deals or M&A to accelerate growth towards Global Specialty Pharma

Booking QINLOCK® sales;
Reinforcement sales
capability in U.S. & EU

Continuous pipeline
creation by R&D
Synergy

Approval of Vimseltinib;
Label expansion of QINLOCK®

Multiple opportunities
for global deal

Approval of otherpipeline from Deciphera

Further growth withmultiple opportunities
for global deal

Strategic growth
after this transaction

Ono Standalone growth

Launch of Velexbru®;
Initiate direct sales
in U.S. & EU

FY2024Itolizumab business Growth;Establish PoC withmultiple ONO assets

Launch with multiple
ONO assets

Note: This image is for illustration purposes only and does not represent actual sales figures or timelines

25 / 25

Dedicated to the Fight against Disease and Pain